Therapeutic medications against diabetes: What we have and what we expect

被引:50
|
作者
Hu, Cheng [1 ,2 ]
Jia, Weiping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Shanghai Diabet Inst,Shanghai Key Lab Diabet Mell, 600 Yishan Rd, Shanghai 200233, Peoples R China
[2] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, South Campus,6600 Nanfeng Rd, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetes; Treatment; Drug delivery; Natural product; GLUCAGON-LIKE PEPTIDE-1; COTRANSPORTER; 2; INHIBITORS; ENCAPSULATES SUBCUTANEOUS IMPLANTS; INADEQUATE GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; BLOOD-GLUCOSE CONCENTRATION; GLP-1 RECEPTOR AGONISTS; BETA-CELL FUNCTION; ORAL DELIVERY; INSULIN DELIVERY;
D O I
10.1016/j.addr.2018.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related complications. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidiabetic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes control, with its greater efficiency, increased bioavailability, decreased toxicity and reduced dosing frequency. Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great potential in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. Our paper aim to overview these therapeutic methods for diabetes therapy. Proper combinations of these existing anti diabetic medications and searching for novel routes are both necessary for better diabetes control. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 50 条
  • [31] DIURETICS - WHAT WE HAVE AND WHAT WE NEED
    KAU, ST
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1987, 37 (01): : 169 - 170
  • [32] COVID-19 and Diabetes: What Should We Expect?
    Pedrosa, Marlus da Silva
    Neves Nogueira, Fernando
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (06): : 1133 - 1134
  • [33] WHAT HAVE WE GOT AGAINST PETS
    SERPELL, J
    NEW SCIENTIST, 1983, 100 (1379) : 80 - 84
  • [34] Enterprise Modeling - What We Have Learned, and What We Have Not
    Jorgensen, Havard D.
    PRACTICE OF ENTERPRISE MODELING, PROCEEDINGS, 2009, 39 : 3 - 7
  • [35] What should we expect when we explant?
    Landes, Uri
    Harari, Emanuel
    EUROINTERVENTION, 2024, 20 (02) : e115 - e116
  • [36] Global change - what do we expect and what do we know?
    Mauser, W
    RESEARCH BASINS AND HYDROLOGICAL PLANNING, 2004, : 53 - 59
  • [37] Nanofluidics: what is it and what can we expect from it?
    Eijkel, JCT
    van den Berg, A
    MICROFLUIDICS AND NANOFLUIDICS, 2005, 1 (03) : 249 - 267
  • [38] OUTCOME INDICATORS FOR DIABETES SERVICES - WHAT DO WE HAVE AND WHAT DO WE NEED
    WILLIAMS, DRR
    COMMUNITY MEDICINE, 1989, 11 (01): : 57 - 64
  • [39] Nanofluidics: what is it and what can we expect from it?
    Jan C. T. Eijkel
    Albert van den Berg
    Microfluidics and Nanofluidics, 2005, 1 : 249 - 267
  • [40] USING WHAT WE HAVE: COMBINING MEDICATIONS TO ACHIEVE REMISSION
    Topel, Michael E.
    Zajecka, John M.
    Goldstein, Corey N.
    Siddiqui, Umar A.
    Schwartz, Thomas L.
    CLINICAL NEUROPSYCHIATRY, 2011, 8 (01): : 4 - 27